Literature DB >> 10375612

Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.

X Y Wen1, A K Stewart, R R Sooknanan, G Henderson, T S Hawley, A M Reimold, L H Glimcher, H Baumann, L T Malek, R G Hawley.   

Abstract

Interleukin-6 (IL-6) is implicated in the in vivo proliferation of malignant plasma cells in multiple myeloma. To define the molecular basis of the IL-6-induced mitogenic response in myeloma cells, we applied STAR (subtractive transcriptional amplification of mRNA), a new differential expression analysis technology, to isolate mRNAs preferentially expressed in IL-6-treated versus untreated cultures of the factor-responsive myeloma cell line U266. From the resulting collection of STAR clones, sequence information was obtained for a total of 72 distinct transcripts. Of these, 29 were found to correspond to known genes, 22 matched expressed sequence tags in public databases and 21 showed no sequence similarity to any existing entries. Among the known genes uncovered in the screen were those encoding proteins that function in cell division, cell signalling and gene/protein expression. Northern blot analysis documented that two transcription factor genes chosen for further study, c-myc promoter-binding protein (MBP-1) and X-box binding protein 1 (XBP-1), were up-regulated in U266 cells about 3-fold relative to the cell cycle-dependent beta-actin gene 12 h after IL-6 treatment. Both genes were also similarly up-regulated by IL-6 in factor-dependent ANBL-6 myeloma cells. These results indicate that MBP-1 and XBP-1 are IL-6 genes in myeloma cells; as such, they may play a role in IL-6-mediated growth control in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375612     DOI: 10.3892/ijo.15.1.173

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Authors:  Sarah Waheed; Alan Mitchell; Saad Usmani; Joshua Epstein; Shmuel Yaccoby; Bijay Nair; Rudy van Hemert; Edgardo Angtuaco; Tracy Brown; Twyla Bartel; James McDonald; Elias Anaissie; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Authors:  A Scuto; P Krejci; L Popplewell; J Wu; Y Wang; M Kujawski; C Kowolik; H Xin; L Chen; Y Wang; L Kretzner; H Yu; W R Wilcox; Y Yen; S Forman; R Jove
Journal:  Leukemia       Date:  2010-12-17       Impact factor: 11.528

Review 3.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 4.  Emerging roles for XBP1, a sUPeR transcription factor.

Authors:  Yin He; Shengyi Sun; Haibo Sha; Ziying Liu; Liu Yang; Zhen Xue; Hui Chen; Ling Qi
Journal:  Gene Expr       Date:  2010

5.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.

Authors:  Duosha Hu; Victoria Wang; Min Yang; Shahed Abdullah; David A Davis; Thomas S Uldrick; Mark N Polizzotto; Ravindra P Veeranna; Stefania Pittaluga; Giovanna Tosato; Robert Yarchoan
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

6.  Phosphatidylcholine as a metabolic cue for determining B cell fate and function.

Authors:  Joseph W Brewer; Viktoriya Solodushko; Ileana Aragon; Robert A Barrington
Journal:  Cell Immunol       Date:  2016-08-03       Impact factor: 4.868

Review 7.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

8.  Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile.

Authors:  Richard G Jenner; Karine Maillard; Nicola Cattini; Robin A Weiss; Chris Boshoff; Richard Wooster; Paul Kellam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

Review 9.  Survival and proliferation factors of normal and malignant plasma cells.

Authors:  Bernard Klein; Karin Tarte; Michel Jourdan; Karene Mathouk; Jerome Moreaux; Eric Jourdan; Eric Legouffe; John De Vos; Jean François Rossi
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

10.  Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.

Authors:  J Bae; R Carrasco; A-H Lee; R Prabhala; Y-T Tai; K C Anderson; N C Munshi
Journal:  Leukemia       Date:  2011-06-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.